- Researchers from University College London, the Francis Crick Institute, AstraZeneca, etc., identified the genetic basis of an increased risk of resistance to treatment of non-small cell lung cancer (NSCLC) in non-smokers. The study was published in Nature Communications.
- The Institute for Bioengineering of Catalonia (IBEC) study showed that different physical properties of colorectal cancer cells had different potential for cancer metastasis. The study was published in Nature Communications.
- Researchers from Stanford University found that, contrary to an earlier FDA warning, the risk of secondary cancers in patients on CAR-T cell therapy is low. The study was published in the New England Journal of Medicine.
- A study found that statins (in particular, pitavastatin), a class of drugs used to lower cholesterol, may be instrumental in suppressing chronic inflammation, a finding that could help prevent inflammatory-related cancers, e.g., pancreatic cancer. The study was published in Nature Communications.
- “Father of tamoxifen”, Pharmacologist V. Craig Jordan, a professor of Breast and Medical Oncology and Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center who discovered selective estrogen receptor modulators and developed breakthrough breast cancer treatment died last week.
- Note: Kendra contributed this entry. The National Institutes of Health is developing a fairly simple (in today’s terms) model to predict whether a given cancer patient will likely respond to immunotherapy. This is a far cry from a large foundational model, but there’s still value in training simpler classifiers. The current state for predicting patient responses to immunotherapy is that one or both biomarkers approved by the FDA will be measured for a particular patient to help oncologists select the drugs most likely to work.
The model in beta right now is described in Nature Cancer (lead author Tian-Gen Chang). The model “makes predictions based on five clinical features that are routinely collected from patients: a patient’s age, cancer type, history of systemic therapy, blood albumin level, and blood neutrophil-to-lymphocyte ratio, a marker of inflammation. The model also considers tumor mutational burden.” The model has shown decent predictive ability and is available here: https://loris.ccr.cancer.gov.